ASH 2020: Dr. Tanya Siddiqi Provides an Update on the TRANSCEND CLL 004 Trial: Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

You are here: